| Literature DB >> 35178179 |
Solida Long1,2, Denise Duarte3, Carla Carvalho4, Rafael Oliveira3, Nuno Santarém4, Andreia Palmeira1,5, Diana I S P Resende1,5, Artur M S Silva6, Rui Moreira7, Anake Kijjoa5,8, Anabela Cordeiro da Silva4,9, Fátima Nogueira3, Emília Sousa1,5, Madalena M M Pinto1,5.
Abstract
Malaria, leishmaniasis, and sleeping sickness are potentially fatal diseases that represent a real health risk for more than 3,5 billion people. New antiparasitic compounds are urgent leading to a constant search for novel scaffolds. Herein, pyrazino[2,1-b]quinazoline-3,6-diones containing indole alkaloids were explored for their antiparasitic potential against Plasmodium falciparum, Trypanosoma brucei, and Leishmania infantum. The synthetic libraries furnished promising hit compounds that are species specific (7, 12) or with broad antiparasitic activity (8). Structure-activity relationships were more evident for Plasmodium with anti-isomers (1S,4R) possessing excellent antimalarial activity, while the presence of a substituent on the anthranilic acid moiety had a negative effect on the activity. Hit compounds against malaria did not inhibit β-hematin, and in silico studies predicted these molecules as possible inhibitors for prolyl-tRNA synthetase both from Plasmodium and Leishmania. These results disclosed a potential new chemotype for further optimization toward novel and affordable antiparasitic drugs.Entities:
Year: 2022 PMID: 35178179 PMCID: PMC8842117 DOI: 10.1021/acsmedchemlett.1c00589
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345